Because it works on the same GLP-1 receptor, experts expect that it will likely carry the same warnings
The trial showed that nearly 63% of patients treated with semaglutide saw hepatitis resolution without fibrosis worsening over 72 weeks of follow-up
After 26, 64 and 76 weeks, 1,392, 359 and 185 patients, respectively, were still taking part in the programme
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
Claim: Higher doses mean faster results Reality: Taking more does not guarantee better outcomes and may increase side effects
SyeA showed better expression than full-length SyeA but remained in the insoluble fraction (Extended Data Fig